Litigation Details for Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)

Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)

Docket		Date Filed	2020-03-26
Court	District Court, D. Delaware	Date Terminated	2023-01-30
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Plaintiff	Referred To
Patents	9,415,085; 9,579,359
Link to Docket	External link to docket

Details for Ferring Pharmaceuticals Inc. v. Fresenius Kabi USA, LLC (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-06-14	141	Order - -Memorandum and Order	of U.S. Patents Nos. 9,579,359 (“the ’359 Patent”), 10,729,739 (“the ’739 Patent”), 9,415,085 (“the ’…the ’081 Patent, the ’999 Patent, U.S. Patent No. 8,828,938 (“the ’938 Patent”), and U.S. Patent No. 10,973,870…359 Patent cl. 1; ’739 Patent cl. 1, 14, 27; ’085 Patent cl. 1; ’398 Patent cl.…claim terms of the ’359 Patent, the ’739 Patent, the ’085 Patent, the ’398 Patent, Case 1:20-cv-00431-MN… The ’359 Patent, ’739 Patent, and ’870 Patent share a first specification, the ’085 Patent and	External link to document
2021-08-13	157	Notice of Service	Objective Evidence of Non-Obviousness of U.S. Patent Nos. 9,415,085 and 10,695,398; (4) Opening Expert Report…F.A.C.S. Regarding Infringement of U.S. Patent Nos. 9,415,085 and 10,695,398; (5) Opening Expert Report…Regarding Objective Evidence of Non-Obviousness of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (6)…Shore, M.D., FACS Regarding Infringement of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (7)…on Objective Evidence of Non-Obviousness of U.S. Patent Nos. 8,841,081 and 9,877,999, and (8) Opening Expert	External link to document
2021-09-17	159	Notice of Service	F.R.C.S.I., F.A.C.S. Regarding Validity of U.S. Patent Nos. 9,415,085 and 10,695,398, and (4) Rebuttal Expert …. Higano, M.D., FACP Regarding Validity of U.S. Patent Nos. 8,841,081 and 9,877,999; (2) Rebuttal Expert…D. Shore, M.D., FACS Regarding Validity of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (3)…2020 30 January 2023 1:20-cv-00431 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2021-10-15	162	Notice of Service	Considerations of Nonobviousness of U.S. Patent Nos. 9,415,085 and 10,695,398, and (5) Reply Expert Report…and Objective Indicia of Nonobviousness of U.S. Patent Nos. 8,841,081 and 9,877,999; (2) Reply Expert …and Objective Indicia of Nonobviousness of U.S. Patent Nos. 9,579,359, 10,729,739, and 10,973,870; (3)…2020 30 January 2023 1:20-cv-00431 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2021-12-15	170		870 patent and the asserted claims of U.S. Patent Nos. 9,415,085 and 10,695,398 (the “CV patents”) are…claims of U.S. Patent No. 10,973,870 (“the ’870 patent”) are invalid as directed to patent ineligible subject…infringe claims of the ’081 patent and the ’999 patent. These two patents are related, which I understand… a Section 101 argument on the CV patent but not on the ’870 patent, Plaintiffs reasonably assumed Fresenius…on the CV patents, Fresenius intended to maintain its Section 101 argument on the ’870 patent while not	External link to document
2022-12-12	223	Opinion - Memorandum Opinion	(“the ’870 patent”), 9,415,085 (“the ’085 patent”), 10,695,398 (“the ’398 patent”), 8,828,938 (“the …The CV Patents The ’085 patent and the ’398 patent (collectively, the “CV patents”) are…” (’359 patent cl. 1; ’739 patent cl. 1, 14, 27; ’085 patent cl. 1; ’398 patent cl. 1, …’359 patent cl. 2; ’739 patent cl. 2, 15, 28; ’085 patent cl. 3, 5, 9; ’398 patent cl. …United States Patent Nos. 9,579,359 (“the ’359 patent”), 10,729,739 (“the ’739 patent”), 10,973,870 (	External link to document
2020-03-26	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,579,359; US 9,415,085; US 8,841,…2020 30 January 2023 1:20-cv-00431 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document